R68070, a combined thromboxane/endoperoxide receptor antagonist (TRA) and thromboxane synthase inhibitor (TSI) , prolongs the bleeding time more than aspirin in man
Hoet, B.; Arnout, J.; Vermylen, J.
Progress in Clinical and Biological Research 301: 573-577
1989
ISSN/ISBN: 0361-7742 PMID: 2552467 Document Number: 344314
Document emailed within 1 workday
Related Documents
De Clerck, F.; Beetens, J.; de Chaffoy de Courcelles, D.; Vercammen, E.; Freyne, E.; Janssen, P.A. 1989: R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade, combined in one molecule Progress in Clinical and Biological Research 301: 567-572Minoguchi, K.; Adachi, M. 2001: Thromboxane A2 synthase inhibitor and receptor antagonist Nihon Rinsho. Japanese Journal of Clinical Medicine 59(10): 1986-1991
Welch, W.J.; Wilcox, C.S.; Dunbar, K.R. 1989: Modulation of renin by thromboxane: studies with thromboxane synthase inhibitor, receptor antagonists, and mimetic American Journal of Physiology 257(4 Pt 2): F554-F560
Gresele, P.; Van Houtte, E.; Arnout, J.; Deckmyn, H.; Vermylen, J. 1984: Thromboxane synthase inhibition combined with thromboxane receptor blockade: a step forward in antithrombotic strategy? Thrombosis and Haemostasis 52(3): 364
Golino, P.; Ambrosio, G.; Gresele, P.; Pascucci, I.; Ragni, M.; Russolillo, E.; Leproux, G.B.; Chiariello, M. 1993: The in vivo antiplatelet effects of thromboxane A2 synthase inhibitors are potentiated by simultaneous thromboxane A2/prostaglandin H2 receptor blockade Journal of Pharmacology and Experimental Therapeutics 266(2): 511-517
Kakinuma, Y.; Miyauchi, T. 2001: Endothelin receptor antagonist, phosphodiesterase inhibitor, thromboxane inhibitor Nihon Rinsho. Japanese Journal of Clinical Medicine 59(6): 1139-1144
De Boer, A.; Kroon, J.M.; Kroon, C.; van Vliet, A.; Schoemaker, H.C.; Breimer, D.D.; Donoghue, S.; Cohen, A.F. 1992: Pronounced effects of the combination of a new thromboxane antagonist (GR32191) and heparin on bleeding time in man Thrombosis and Haemostasis 68(1): 24-29
Weber, C.; Beetens, J.R.; Tegtmeier, F.; Van Rooy, P.; Vercammen, E.; Wouters, L.; De Clerck, F. 1992: Ridogrel inhibits systemic and renal formation of thromboxane A2 and antagonizes platelet thromboxane A2/prostaglandin endoperoxide receptors upon chronic administration to man Thrombosis and Haemostasis 68(2): 214-220
Nanji, A.A.; Rahemtulla, A.; Maio, L.; Khwaja, S.; Zhao, S.; Tahan, S.R.; Thomas, P. 1997: Alterations in thromboxane synthase and thromboxane A2 receptors in experimental alcoholic liver disease Journal of Pharmacology and Experimental Therapeutics 282(2): 1037-1043
Nakayama, D.; Ikeda, T. 1988: Effect of OKY-046, a thromboxane synthetase inhibitor, on renal thromboxane synthesis in spontaneously hypertensive rat Nihon Jinzo Gakkai Shi 30(1): 79-84
Chiabrando, C.; Broggini, M.; Castelli, M.G.; Cozzi, E.; Castagnoli, M.N.; Donelli, M.G.; Garattini, S.; Giavazzi, R.; Fanelli, R. 1987: Prostaglandin and thromboxane synthesis by M5076 ovarian reticulosarcoma during growth: effects of a thromboxane synthetase inhibitor Cancer Research 47(4): 988-991
Ishiura, Y.; Fujimura, M.; Myou, S.; Amemiya, T.; Nobata, K.; Liu, Q.; Yamamori, C.; Matsuda, T. 2000: Effect of thromboxane synthase inhibitor, CS-518, on propranolol-induced bronchoconstriction in guinea pigs Drugs under Experimental and Clinical Research 26(2): 33-40
Pill, J.; Wolf, O.; Schmelz, A.; Stegmeier, K.; Metz, J. 1990: Investigations of the antiatherosclerotic effect of the thromboxane A2 receptor antagonist Daltroban Zeitschrift für Kardiologie 79(Suppl 3): 155-160
Schumacher, W.A.; Heran, C.L.; Hartl, K.S.; Ogletree, M.L. 1990: Activity of the short-acting thromboxane receptor antagonist, SQ 30,741, in thrombolytic and vasospastic models in monkeys Journal of Pharmacology and Experimental Therapeutics 253(2): 841-846
Higo, K.; Sano, J.; Karasawa, A.; Kubo, K. 1993: The novel thromboxane A2 receptor antagonist KW-3635 reduces infarct size in a canine model of coronary occlusion and reperfusion Archives Internationales de Pharmacodynamie et de Therapie 323: 32-49
Hillbom, M.; Muuronen, A.; Löwbeer, C.; Anggård, E.; Beving, H.; Kangasaho, M. 1985: Platelet thromboxane formation and bleeding time is influenced by ethanol withdrawal but not by cigarette smoking Thrombosis and Haemostasis 53(3): 419-422
Ennis, C.; Granger, S.E.; Middlefell, V.C.; Philpot, M.E.; Shepperson, N.B. 1989: Pharmacologic effects of Wy 27569: a combined calcium channel blocker and thromboxane synthetase inhibitor Journal of Cardiovascular Pharmacology 13(4): 511-519
Karasawa, A.; Kawakage, M.; Shirakura, S.; Higo, K.; Kubo, K.; Ohshima, E.; Obase, H. 1991: Antiplatelet effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e] oxepine-2-carboxylate monohydrate Arzneimittel-Forschung 41(12): 1230-1236
Sasao, J.; Taneyama, C.; Kimura, M.; Kiyono, S. 1989: The effects of ONO 3708, a new thromboxane receptor antagonist, on cardiovascular response during the early phases of endotoxin shock in anesthetized dogs Masui. Japanese Journal of Anesthesiology 38(9): 1188-1194
Grover, G.J.; Schumacher, W.A. 1989: Effect of the thromboxane A2 receptor antagonist SQ 30,741 on ultimate myocardial infarct size, reperfusion injury and coronary flow reserve Journal of Pharmacology and Experimental Therapeutics 248(2): 484-491